

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 March 2022 (24.03.2022)



(10) International Publication Number
WO 2022/058445 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 16/46 (2006.01)
A61P 35/02 (2006.01) A61K 39/00 (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/EP2021/075523

(22) International Filing Date:

16 September 2021 (16.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/079,294 16 September 2020 (16.09.2020) US
63/116,549 20 November 2020 (20.11.2020) US
63/187,888 12 May 2021 (12.05.2021) US

(71) Applicant: **JANSSEN PHARMACEUTICA NV**
[BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).

(72) Inventors: **GIRGIS, Suzette**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **GOLDBERG, Jenna**; 920 US Highway 202 South, Raritan, New Jersey 08869 (US). **HILDER, Brandi**; 1400 McKean Road, Spring

House, Pennsylvania 19477 (US). **MA, Xuewen**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **RUSSELL, Jeffery**; 5121 S. Sandpiper Drive, #449, Salt Lake City, Utah 84117 (US). **VERONA, Raluca**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **YANG, Shiyi**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **PILLARISETTI, Kodandaram**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US).

(74) Agent: **DUFFIELD, Stephen** et al.; Carpmals & Ransford LLP, One Southampton Row, London WC1B 5HA (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: METHODS FOR TREATING MULTIPLE MYELOMA




Figure 4

(57) Abstract: Methods of treating a hematological malignancy using a GPRC5DxCD3 bispecific antibody are described. The hematological malignancy can be a relapsed or refractory multiple myeloma, and the GPRC5DxCD3 bispecific antibody can be talquetamab.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*